Novitium Pharma's Butalbital Combination Receives FDA Submission Approval
The FDA has approved a supplemental application for a combination product containing Butalbital, Aspirin, Caffeine, and Codeine Phosphate by Novitium Pharma.
Asset / Drug
Drug and asset intelligence for Novitium with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.